Scroll Back to Top
Accessibility
Accessibility
Lung-Getty-530082112-mobile

Lung Cancer 

Labcorp Oncology offers a comprehensive test menu to assist in the diagnosis and management of patients with lung cancer throughout their continuum of care.

supporting image

  Diagnostic  |  Prognostic  |  Biomarkers for Therapeutic Selection

Diagnostic Icon

Diagnostic

Diagnostic

Complex Tumor Analysis by IHC

Learn more about Complex Tumor Analysis by IHC

Our extensive antibody library and team of pathologists can provide a differential diagnostic analysis in even the most difficult cases.

  • Squamous cell vs. adenocarcinoma
  • Adenocarcinoma vs. mesothelioma
  • Lung vs. breast
  • Small cell vs. non-small cell carcinoma

Learn more about Complex Tumor Analysis by IHC

Clipboard Icon

Prognostic

Prognostic

KRAS Gene Mutation
Analysis, IVD

Learn more about KRAS Gene Mutation
Analysis, IVD

 The presence of a KRAS mutation is prognostic for poor survival.1

Learn more about KRAS Gene Mutation
Analysis, IVD

Predictive icon

Biomarkers for Therapeutic Selection

Biomarkers and tests for clinical management and treatment decision-making

TestDetectsTherapy
ALK (D5F3) by IHCALK protein expressionalectinib2, brigatinib3, lorlatinib4, ceritinib5, crizotinib6
ALK by FISHALK rearrangements (translocations)alectinib2, brigatinib3, lorlatinib4, ceritinib5, crizotinib6
BRAF Gene Mutation AnalysisMutations in the BRAF gene (V600E)dabrafenib7 + trametinib8, vemurafenib9
EGFR Mutation Analysis Cobas V2 Assay (tissue and plasma)Mutations in the EGFR geneosimertinib10, gefitinib11, erlotinib12, afatinib13,dacomitinib14
EGFR by FISHEGFR amplificationosimertinib10, gefitinib11, erlotinib12, afatinib13,dacomitinib14
KRAS Mutation Analysis, IVDMutations in the KRAS gene (G12C)sotorasib15, adagrasib16
Labcorp® Plasma Complete™ A comprehensive ctDNA liquid biopsy test for solid tumors that evaluates 521 genes Informs the selection of targeted treatment options across pan-solid tumors
MET by FISHMET amplificationcrizotinib6
Microsatellite Instability (MSI) by PCR or Mismatch Repair (MMR) Proteins by IHCMicrosatellite instability/Mismatch repair (MMR) deficiencypembrolizumab17
OmniSeq INSIGHT, Solid Tumor NGS Panel (DNA and RNA)Includes PD-L1 IHC, DNA and RNA sequencing (523 genes), MSI, TMB*, fusion analysis including NTRK and RET, and immune gene profilingTargeted therapies and immunotherapies
PD-L1 by IHC (22C3, SP263, SP142, 28-8 clones)PD-L1 protein expressionpembrolizumab17, nivolumab18, atezolizumab19, cemiplimab-rwlc20
RET by FISHRET rearrangements (translocations)selpercatinib21, pralsetinib22, cabozantinib23
ROS1 by FISHROS1 rearrangements (translocations)crizotinib6, ceritinib5, entrectinib22, repotrectanib25

References

  1. Slebos, R.J., et al., K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990 Aug 30;323(9):561-5. 
  2. ALECENSA® (alectinib) [package insert]. South San Francisco, CA: Genentech, Inc.; 2021.
  3. ALUNBRIGTM (brigatinib) [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; 2017.
  4. LORBRENA® (lorlatinib) [package insert]. New York, NY: Pfizer, Inc.; 2021.
  5. ZYKADIA® (ceritinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019.
  6. XALKORI® (crizotinib) [package insert]. New York, NY: Pfizer, Inc.; 2022.
  7. TAFINLAR® (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.
  8. MEKINIST® (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2022.
  9. ZELBORAF® (vemurafenib) [package insert]. South San Francisco, CA: Genentech, Inc.; 2021.
  10. TAGRISSO® (osimertinib) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.
  11. IRESSA® (gefitinib) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2021.
  12. TARCEVA® (erlotinib) [package insert]. South San Francisco, CA: Genentech, Inc.; 2010.
  13. GILOTRIF® (afatinib) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2018.
  14. VIZIMPRO® (dacomitinib) [package insert]. New York, NY: Pfizer, Inc.; 2018.
  15.  LUMAKRAS™ (sotorasib) [package insert]. Thousand Oaks, CA: Amgen Inc.; 2021.
  16. KRAZATI® (adagrasib) [package insert]. San Diego, CA: Mirati Therapeutics, Inc.; 2022.
  17. KEYTRUDA® (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck &Co., Inc.; 2021.
  18. OPDIVO® (nivolumab) [package insert]. Princeton, NJ: : Bristol-Myers Squibb Company; 2018.
  19. TECENTRIQ® (atezolizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2018.
  20. LIBTAYO® (cemiplimab-rwlc) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2021.
  21. RETEVMO™ (selpercatinib) [package insert]. Indianapolis, IN: Lilly USA, LLC; 2021.
  22. GAVRETO™ (pralsetinib) [package insert]. Cambridge, MA: : Blueprint Medicines Corporation; 2020.
  23. CABOMETYX® (cabozantinib) [package insert]. Alameda, CA: Exelixis, Inc.; 2019.
  24. ROZLYTREK™ (entrectinib) [package insert]. South San Francisco, CA: Genentech, Inc.; 2019.
  25. Turning Point Therapeutics granted breakthrough therapy designation for repotrectinib treatment in patients with one prior ROS1 tyrosine kinase inhibitor and no prior chemotherapy. Press Release.  Turning Point Therapeutics; May 10, 2023. https://www.tptherapeutics.com/news-release/news-release-details/turning-point-therapeutics-granted-breakthrough-therapy-0/